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Phenotypic screening of the ‘Kurz-box’ 
of chemicals identifies two compounds (BLK127 
and HBK4) with anthelmintic activity in vitro 
against parasitic larval stages of Haemonchus 
contortus
Linh Thuy Nguyen1,2, Thomas Kurz3, Sarah Preston1,4, Hjoerdis Brueckmann3, Beate Lungerich3, 
H. M. P. Dilrukshi Herath1, Anson V. Koehler1, Tao Wang1, Lenka Skálová2, Abdul Jabbar1 and Robin B. Gasser1*
Abstract 
Background: Due to anthelmintic resistance problems, there is a need to discover and develop new drugs for the 
treatment and control of economically important and pathogenic nematodes of livestock animals. With this focus 
in mind, we screened 236 compounds from a library (called the ‘Kurz-box’) representing chemically diverse classes 
such as heterocyclic compounds (e.g. thiazoles, pyrroles, quinolines, pyrimidines, benzo[1,4]diazepines), hydoxamic 
acid-based metalloenzyme inhibitors, peptidomimetics (bis- and tris-pyrimidoneamides, alkoxyamides) and various 
intermediates on Haemonchus contortus, one of the most important parasitic nematodes of ruminants.
Methods: In the present study, we tested these compounds, and measured the inhibition of larval motility and 
development of exsheathed third-stage (xL3) and fourth-stage (L4) larvae of H. contortus using an optimised, whole-
organism phenotypic screening assay.
Results: Of the 236 compounds, we identified two active compounds (called BLK127 and HBK4) that induced 
marked phenotypic changes in the worm in vitro. Compound BLK127 induced an ‘eviscerated’ phenotype in the xL3 
stage and also inhibited L4 development. Compound HBK4 exerted a ‘curved’ phenotype in both xL3s and L4s.
Conclusions: The findings from this study provide a basis for future work on the chemical optimisation of these com-
pounds, on assessing the activity of optimised compounds on adult stages of H. contortus both in vitro and in vivo (in 
the host animal) and against other parasitic worms of veterinary and medical importance.
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Background
Parasitic worms (helminths) cause a major disease 
burden on humans and animals worldwide. A highly 
pathogenic parasitic nematode of livestock animals is 
Haemonchus contortus, also known as the barber’s pole 
worm. This species is recognised as one of the most eco-
nomically important parasites of ruminants, because it 
impairs weight gain and productivity, and causes disease 
and mortality, particularly in young animals [1]. Sheep 
and goats with large burdens of H. contortus develop 
anaemia and can die in the absence of effective treatment.
Although available anthelmintics including benzimi-
dazoles, imidazothiazoles, macrocyclic lactones, salicy-
lanilides, amino-acetonitrile derivatives or spiroindoles 
[1] are used for the treatment of parasitic nematodes, 
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chemical control is becoming less effective due to the 
occurrence of resistance to one or multiple drugs. The 
high genetic diversity of H. contortus gives rise to the 
rapid selection of resistant worms, whose survival 
favours the spread of alleles bearing drug resistance traits 
to progeny [2–4]. Moreover, the regular, if not excessive 
use of chemical treatment and management practices 
contribute to increased selection pressure in subse-
quent worm generations. Drug resistance is now very 
widespread in parasitic nematodes of particularly small 
ruminants [1, 5], and there are reports of resistance to, 
or reduced efficacy of, some recently commercialised 
anthelmintics, such as monepantel or derquantel [6, 7]; 
there is also an increased prevalence of multi-drug-resist-
ant strains [5, 8].
Even though non-chemical methods for parasite control 
in livestock animals (e.g. nutrition or vaccines) can reduce 
the reliance on the use of chemicals and are environmen-
tally friendly, none of these methods appear yet sufficiently 
effective without complementary anthelmintic treatment 
measures [9]. In order to reduce the burden caused by para-
sites, such as H. contortus, in small ruminants, control pro-
grammes can be based on integrated parasite management 
[1], which takes into account economic factors including 
epidemiology, resistance status as well as animal produc-
tion and management systems. Nonetheless, anthelmintic 
treatment is usually central to parasite control.
Therefore, the discovery of novel chemical entities with 
unique modes of action against drug-resistant nema-
todes of livestock is critical. In this context, we have 
commenced a programme to screen several distinct 
compound libraries [10–16] against H. contortus, a rep-
resentative strongylid nematode, using a whole-organism 
phenotypic screening technique established in our labo-
ratory [10]. In the present study, we expand this work 
by screening a set of compounds (n = 236) representing 
distinct classes of chemicals, including heterocyclic com-
pounds (e.g. thiazoles, pyrroles, quinolines, pyrimidines, 
benzimidazoles, benzo[1,4]diazepines), hydoxamic acid-
based metalloenzyme inhibitors, peptidomimetics (bis- 
and tris-pyrimidoneamides, alkoxyamides) and various 
intermediates. The aims of the present study were to 
(i) undertake a primary screen of the chemicals against 
exsheathed third-stage (xL3) larvae and identify active 
(‘hit’) compound/s; (ii) assess the activity and potency of 
active compounds at inhibiting xL3 and L4 motility and 
L4 development in a dose–response assay; and (iii) char-
acterise the non-wild-type phenotypes of treated larvae.
Methods
Procurement of H. contortus
The Haecon-5 strain (Australia, cf. [17]) of H. contor-
tus was maintained in experimental sheep as described 
previously [10], in accordance with institutional animal 
ethics guidelines (permit no. 1613878; The University of 
Melbourne, Australia). L3s were produced from H. con-
tortus eggs by incubating humidified faeces from infected 
sheep at 27 °C for 1 week and stored for ≤ 3 months [10]. 
To produce xL3s, L3s were exposed to 0.15% (v/v) of 
sodium hypochlorite (NaClO) for 20 min at 37 °C [10], 
washed five times in sterile physiological saline and cul-
tured in Luria Bertani medium (LB) supplemented with 
final concentrations of 100 IU/ml of penicillin, 100 µg/ml 
of streptomycin and 2 µg/ml of amphotericin (LB*). To 
produce L4s, xL3s were incubated for 7 days at 38 °C and 
10% (v/v)  CO2, when ≥ 80% of xL3s had developed to the 
L4 stage.
Preparation of compounds for screening
The compound library (designated ‘Kurz-box’) contain-
ing 236 chemicals was assembled and curated by two of 
the authors (TK and BL) at the Institute of Pharmaceuti-
cal and Medicinal Chemistry, Heinrich-Heine-University 
Düsseldorf, Germany. Individual compounds were dis-
solved in 100% dimethyl sulfoxide (DMSO) to achieve 
stock concentrations of 20 mM. Individual compounds 
were then diluted in LB* and tested for activity against H. 
contortus. The synthesis of the ‘hit’ compounds is given in 
Additional file 1.
Screening of compounds for their effect on xL3 motility 
and L4 development
The whole-organism screening assay, developed by Pres-
ton et  al. [10], was used to evaluate the effect of com-
pounds on the motility of xL3s of H. contortus. In the 
primary screen, xL3 motility was assessed for each com-
pound (at the final concentration of 20 µM and using 
three technical replicates) as described previously [10]. 
Two commercial drugs, monepantel (Zolvix, Novartis 
Animal Health, Switzerland) and moxidectin (Cydectin, 
Virbac, France), were used as the positive controls (at the 
final concentration of 20 µM), and LB* + 0.5% DMSO 
was used as the negative control. Following an incubation 
period of 72 h (38 °C, 10% (v/v)  CO2), a 5 s video record-
ing was taken of each well to capture the motility of xL3s. 
The plates were then incubated for 4 more days to observe 
the effect of individual compounds on the development 
of L4s. After 7 days, a 5 s video was taken for each well. 
Then, worms were fixed with 50 µl of 1% iodine; L4s were 
identified microscopically (magnification of 20×) based 
on the presence of a well-developed pharynx characteris-
tic of H. contortus [18] and counted. Length and width of 
L4s (n = 30) were measured and assessed for phenotypic 
changes using the software program ImageJ (National 
Institutes of Health, Bethesda, MD, USA). Width was 
measured at the level of nerve-ring (cf. [19]). Results were 
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expressed as mean ± standard error of the mean (SEM). 
The number of L4s was expressed as a percentage of the 
total number of worms counted. The one-way analysis of 
variance (ANOVA) and Dunnett’s multiple comparison 
tests were used to compare the effect of compounds on 
L4 development in comparison to the negative control. If 
the compound reduced the xL3 motility by > 70% and/or 
induced phenotypic changes compared with the negative 
control after 7 days, it was recorded as a ‘hit’ compound.
Dose–response assessments of identified active 
compounds on xL3 and L4 motility, and L4 growth 
and development
The motility of xL3s was assessed in an 18-point dose–
response curve (two-fold serial dilutions; from 100 µM 
to 0.00076 µM). On each 96-well plate, test compounds 
and the positive controls (monepantel and/or moxidec-
tin) were arrayed in triplicate. Six wells were used for the 
negative control (LB* + 0.5% DMSO) on each plate. A 5 
s video recording was taken of each well after 24 h, 48 h 
and 72 h [10]. The culture plates were then incubated for 
4 more days at 38  °C, 10% (v/v)  CO2. After a total of 7 
days, a 5 s video recording was taken of each well, and 
motility was recorded using the motility algorithm [10], 
after which the worms were fixed with 50 µl of 1% iodine. 
L4 development was assessed as described [10].
The motility of L4s was evaluated using the same pro-
tocol as for xL3s [10]. The motility was measured after 
24, 48 and 72 h of incubation of L4s with each active 
compound (triplicate). At the end of L4 motility assay, i.e. 
after 72 h, worms were observed using light microscope 
(DP26 camera, Olympus) to determine the structural 
changes induced by the compounds.
Compound concentrations were transformed using 
the equation x = log10 (concentration in µM) and a 
log(inhibitor) versus response - variable slope (four 
parameter) equation in GraphPad Prism v.7.04 was used 
to calculate the half maximum inhibitory concentration 
 (IC50), where possible.
Results
Identification of two active compounds with characteristic 
phenotypic changes in H. contortus
In the primary screen of 236 chemicals, none of the com-
pounds inhibited xL3 motility by > 70% after 72 h. How-
ever, incubation of culture plates for 4 more days revealed 
that two compounds induced phenotypic changes in 
the larvae (Fig. 1, Additional file 1). Compound BLK127 
induced an anterior protrusion in xL3s (treated for 7 
days); compound HBK4 induced a ‘curved’ phenotype in 
xL3s (7 days) and L4s (24 h) (Fig. 2).
Fig. 1 Chemical structure, IUPAC name and molecular weight  (Mw) of the two compounds that were recorded to affect Haemonchus contortus in 
the present study
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Fig. 2 Light microscopy images of different phenotypes of exsheathed third-stage larvae (xL3) or developed fourth-stage larvae (L4) of 
Haemonchus contortus 7 days following exposure of xL3s to 20 µM of compound BLK127, HBK4, monepantel (positive control) or LB* + 0.5% 
DMSO (negative control). The details of the developed pharynx in the negative control, anterior protrusion in the ‘eviscerated’ (Evi) phenotype and 
presence of vacuoles in the ‘curved’ phenotype are shown. Scale-bars are 50 µm and 20 µm for 40× and 100× magnification, respectively
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The phenotypic changes recorded by video in xL3s 
after 7 days were examined further by light microscopy. 
A detailed examination of BLK127-treated xL3s revealed 
an ‘eviscerated’ (Evi) phenotype, consistent with that 
described by Jiao et al. [20].
Larvae with an Evi phenotype retained their old cuticle, 
and some of the xL3s with a protrusion had a developed 
pharynx. However, the severe morphological damage 
induced by compound BLK127 appeared not to allow lar-
vae to moult to the next stage and resulted in death of the 
larvae. During the physiological process of ecdysis, the 
old cuticle breaks approximately at the level of the excre-
tory pore, and the cuticle swells and becomes distorted in 
this region prior to rupturing [19]. The xL3s exposed to 
BLK127 gradually (over a period of 72 h) eviscerated and 
released fluids via the excretory pore (108.4 ± 1.2 µm, 
n = 30). The expelled mass extruded through the rupture 
in the cuticle, and the protrusion was located 80.7 ± 1.5 
µm from the anterior tip of the xL3 stage (n = 30).
In the primary screen, compound BLK127 significantly 
(one-way ANOVA and Dunnett’s multiple compari-
son test: F(4,13) = 257.5, P < 0.0001) reduced L4 develop-
ment at a concentration of 20 µM, with 52% of treated 
worms developing to L4s within 7 days (Fig.  3). In a 
dose–response assay, the first concentration at which Evi 
phenotype was detected with the significant difference 
(one-way ANOVA and Dunnett’s multiple comparison 
test: F(18,114) = 144.0, P < 0.0001) from the untreated con-
trol was 6.25 µM (Fig. 4a); at this concentration, 25% of 
xL3s had an Evi phenotype. At the highest tested con-
centration of 100 µM, 30% of larvae developed to the L4 
stage, and 46% of the remaining xL3s had the Evi phe-
notype. From the highest concentration to 25 µM, the 
percentages of xL3s with/without the Evi phenotype 
were similar. From the dose–response curves, the  IC50 
values for the inhibition of L4 development by com-
pound BLK127 and monepantel were 7.98 ± 0.68 µM and 
0.04 ± 0.01 µM, respectively (Fig. 4b). The Evi phenotype 
was induced only during treatment of xL3s, but not L4s.
Compound HBK4 induced a particular ‘curved’ xL3 
phenotype in the primary screen. Irrespective of the 
‘curved’ phenotype, L4 development did not appear to 
be inhibited, as most xL3s (95%) developed to L4s when 
exposed to HBK4 at a concentration of 20 µM (Fig. 3). 
However, the length of L4s that developed from xL3s 
exposed to HBK4 for 7 days (693 ± 15 µm) was signifi-
cantly shorter (unpaired t-test: t(32) = 2.428, P = 0.0210) 
than the untreated control group (measuring 745 ± 14 
µm); nonetheless, the width of HBK4-treated L4s 
(18.3 ± 0.3 µm) was not significantly different from 
the untreated control group (18.9 ± 0.6 µm) (unpaired 
t-test: t(32) = 0.9374, P = 0.3556). The ‘curved’ pheno-
type was also observed in the dose–response motil-
ity assays (for both xL3s and L4s) at concentrations 
beyond 6.25 µM (i.e. 100 µM, 50 µM, 25 µM and 12.5 
µM). The most remarkable alterations associated with 
larvae with the ‘curved’ phenotype were observed in the 
intestine and the cuticle of L4s after 72 h of exposure 
to compound HBK4. By comparison with untreated 
controls, affected larvae had a disorganised internal 
structure and the presence of variable numbers of vac-
uoles of distinct sizes within the intestinal cells in the 
middle part of the body. No obvious alterations in the 
cephalic region, including pharynx and oesophagus, 
were detected by light microscopy. Another marked 
alteration was cuticular wrinkling, which commenced 
in the transition between oesophagus and intestine and 
continued to the distal part of the gut. Similar mor-
phological changes were also observed in L4s treated 
with monepantel at concentrations of between 25 µM 
and 100 µM. However, in the primary screen, monep-
antel resulted in a particular ‘coiled’ phenotype (Fig. 2; 
cf. [11, 13]). With respect to untreated controls, it was 
observed that HBK4-treated L4s with cuticular wrin-
kling were still capable of a limited range of movement 
only within the head or tail region, whereas larvae with 
vacuoles were immobile.
Fig. 3 Development of fourth-stage larvae (L4s) (%) after 7 days 
of exposure to 20 µM of individual compounds; **** denotes 
significance: P < 0.0001 compared to the negative control (NC) 
LB* + 0.5% DMSO based on one-way ANOVA and Dunnett’s multiple 
comparison test
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Fig. 5 Dose–response curves for test compounds BLK127 and HBK4 
on larval stage of Haemonchus contortus in vitro. Inhibition of larval 
motility after 7 days of exposure of exsheathed third-stage larvae to 
test or control (monepantel) compounds. Each data point represents 
the mean of three experiments (± standard error of the mean, SEM)
Fig. 4 Effect of the compound BLK127 on the development of exsheathed third-stage larvae (xL3) to the fourth-stage (L4) after 7 days. a 
Percentage of L4, xL3 with/without evisceration (Evi) phenotype with reference to a negative (untreated) control (NC) LB* + 0.5% DMSO. b Dose–
response curve for inhibition of L4 development. L4 development was assessed by light microscopy. **** denotes significance: P < 0.0001 compared 
to the NC
Effects of two identified active compounds on inhibiting 
xL3 and L4 motility in a dose–response assay
Although compounds BLK127 and HBK4 did not sig-
nificantly reduce xL3 motility, even at the highest con-
centration of 100 µM for 72 h, they did inhibit larval 
motility at 7 days, with  IC50 values of 7.45 ± 1.76 µM 
and 12.17 ± 2.28 µM, respectively (Fig.  5). Compounds 
BLK127 and HBK4 reproducibly inhibited L4 motility 
at concentrations from 12.5 µM to 100 µM and from 25 
µM to 100 µM, respectively. Significance between values 
determined by one-way ANOVA and Dunnett’s multiple 
comparison tests were: P = 0.0018 at 12.5 µM, P = 0.0051 
at 25 µM, P < 0.0001 at 50 µM and 100 µM; df = 4, F(4, 
48) = 55.19 for compound BLK127; and P < 0.0001 at 50 
µM and 100 µM; df = 3, F(3, 36) = 92.22 for compound 
HBK4 (Fig. 6).
Page 7 of 9Nguyen et al. Parasites Vectors          (2019) 12:191 
Discussion
Of the 236 chemicals screened, two compounds, desig-
nated BLK127 and HBK4 (cf. Fig. 1), induced phenotypic 
alterations in larval stages of H. contortus.
The first compound, BLK127, induced an Evi pheno-
type, which is likely linked to an adverse effect of this 
compound on the excretory/secretory system (cf. [20]). 
The excretory pore is assumed to have an osmoregula-
tory function as well as a role in exsheathment [21]. The 
excretory system has been suggested as the source of the 
exsheathment fluid, which contains enzymes capable of 
degrading components of the cuticle [22]. In general, 
after hatching from an egg, H. contortus undergoes four 
larval moults from L1 to the adult stage [23, 24]. These 
steps appear to be tightly controlled by particular path-
ways and genes [25], and dysregulation thereof results in 
moulting defects and/or lethality [24].
The results for the L4 development assay after 7 days 
revealed significantly less L4s following exposure to 
BLK127 in relation to the untreated controls. It appears 
that the process of moulting from xL3 to the L4 stage is 
(partially) suppressed, and it was observed that most lar-
vae retained their previous cuticle. It was suggested that 
pathways that govern exsheathment and development 
are distinct, although the external stimuli for these pro-
cesses appear to be shared, to some extent, particularly 
in early life-cycle stages [26]. The process of moulting 
and its modulatory factors have been well-studied in the 
free-living nematode Caenorhabditis elegans. The factors 
that control nematode moulting are still relatively elusive, 
but there is evidence linking steroid hormones and cho-
lesterol to moulting defects in mutant C. elegans [27, 28]. 
As would be expected, a number of genes encoding both 
structural components of the cuticle and enzymes that 
modify cuticular proteins have been identified in screens 
for moulting-defective mutants [24].
Compound HBK4 was the second ‘hit’ compound 
from the random chemical collection, ‘Kurz-box’, and is 
a benzimidazole derivative. Benzimidazoles are a class of 
widely-used anthelmintic agents with a relatively broad 
spectrum of activity against gastrointestinal worms [1]. 
Even though the Haecon-5 strain of H. contortus is par-
tially benzimidazole resistant (cf. [11, 17]), compound 
HBK4 induced a ‘curved’ phenotype at the L4 stage 
(Fig.  2). This phenotype has not been observed previ-
ously, although other phenotypes have. For instance, two 
pyrazole-5-carboxamide derivatives have been reported 
to induce a ‘straight’ phenotype after 72 h of exposure 
of xL3 [29], contrasting a ‘coiled’ phenotype induced by 
monepantel [11].
The present results showed that compound HBK4 was 
markedly more potent on L4s than xL3s. Similar find-
ings have been made for other ‘hit’ compounds, includ-
ing tolfenpyrad [11], SN00797439 [14] and deguelin [15]. 
This difference in potency might relate, for example, to 
a difference in the extent of compound uptake (via the 
mouth and alimentary tract) or metabolism between 
these two developmental stages. Nevertheless, further 
light microscopic examination of this non-wild type lar-
val phenotype revealed changes in the cuticle and inter-
nal structures.
The cuticle is important in that it gives a worm its 
shape, provides protection and allows some metabolic 
exchanges with the surrounding environment [30]. 
Therefore, we assume that the structural cuticular dis-
turbances observed here might lead to a possible impair-
ment in the movement of the worm and, ultimately, 
death of the worm. Studies of H. contortus have also iden-
tified cuticular damage by scanning electron microscopy 
[14, 31]. Regarding the second observed morphological 
change, the formation of vacuoles had been recorded 
in early experiments [19]. The author of the latter study 
Fig. 6 Assessment of the effect of test compounds BLK127 and HBK4 on inhibition of the fourth-stage larvae (L4) motility at selected 
concentrations at 72 h compared with negative control (LB* + 0.5% DMSO; NC). Statistical significance in comparison to NC: **P < 0.01; 
****P < 0.0001
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observed that L3s exposed to unfavourable conditions, 
such as desiccation, light or heat, developed vacuoles 
mainly in the intestinal cells at different time points, 
depending on the conditions and media used. The occur-
rence of many such vacuoles indicates that larvae were 
nearing death [19], which is consistent with the present 
study where larvae with vacuoles were immotile. The dis-
organised internal structures of treated larvae indicate 
that the two compounds identified herein induce pheno-
types that are not compatible with the life of a worm.
Future work could focus on further evaluating the phe-
notypic and pathophysiological changes in the worms as 
well as the mechanisms underlying these changes. The 
morphology of worms could be assessed directly and, in 
more detail, using confocal microscopy or scanning elec-
tron microscopy. Nowadays, the coherent anti-Stokes 
Raman scattering spectroscopy [32–34] enables the dis-
tribution of lipids to be assessed in a rapid and label-free 
manner; this method could explore compositional dif-
ferences between treated and untreated larvae, mainly 
in the intestinal tract, where significant alterations were 
seen here.
Conclusions
The results of the present study provide a sound basis 
for future work, aimed at identifying one or more new 
anthelmintics and their targets. The phenotypic altera-
tions induced by compounds BLK127 and HBK4 in 
H. contortus might stimulate further pharmacological 
research, as there has been interest in finding new agents 
that interfere with moulting in nematodes [35]. Moreo-
ver, assessing the activity of these compounds against 
other socioeconomically important parasites and their 
biotransformation would be interesting.
Additional file
Additional file 1. Synthesis and features of chemicals HBK4 and BLK127 in 
the present study.
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